Intensity Therapeutics/$INTS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Intensity Therapeutics
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Ticker
$INTS
Sector
Primary listing
Employees
6
Headquarters
INTS Metrics
BasicAdvanced
$20M
-
-$12.79
4.22
-
Price and volume
Market cap
$20M
Beta
4.22
52-week high
$8.06
52-week low
$5.40
Financial strength
Current ratio
3.597
Quick ratio
3.105
Long term debt to equity
1.205
Total debt to equity
1.634
Profitability
Management effectiveness
Return on assets (TTM)
-101.66%
Return on equity (TTM)
-234.70%
Valuation
Price to book
2.16
Price to tangible book (TTM)
2.16
Price to free cash flow (TTM)
-0.768
Free cash flow yield (TTM)
-130.18%
Free cash flow per share (TTM)
-10.35
Growth
Earnings per share change (TTM)
-56.76%
3-year earnings per share growth (CAGR)
-40.96%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intensity Therapeutics stock?
Intensity Therapeutics (INTS) has a market cap of $20M as of March 07, 2026.
What is the P/E ratio for Intensity Therapeutics stock?
The price to earnings (P/E) ratio for Intensity Therapeutics (INTS) stock is 0 as of March 07, 2026.
Does Intensity Therapeutics stock pay dividends?
No, Intensity Therapeutics (INTS) stock does not pay dividends to its shareholders as of March 07, 2026.
When is the next Intensity Therapeutics dividend payment date?
Intensity Therapeutics (INTS) stock does not pay dividends to its shareholders.
What is the beta indicator for Intensity Therapeutics?
Intensity Therapeutics (INTS) has a beta rating of 4.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.